查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813868

药物基因体学中的分子诊断市场规模、份额和趋势分析报告：按产品、治疗领域、技术、地区和细分市场预测，2025-2033 年

Molecular Diagnostics In Pharmacogenomics Market Size, Share & Trends Analysis Report By Product (Kits & Assays, Reagents, Services), By Therapeutic Area, By Technology, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

药物基因体学中的分子诊断市场摘要

预计 2024 年全球药物基因药物基因体学诊断市场价值将达到 6.997 亿美元，到 2033 年将达到 12.5638 亿美元，2025 年至 2033 年的复合年增长率为 6.84%。

该市场专注于快速且准确的基因检测，以实现个人化药物治疗、改善临床结果并减少药物不良反应。

分子诊断在识别患者特异性基因突变方面发挥核心作用，广泛应用于肿瘤学、心血管疾病、感染疾病和神经系统疾病等领域。市场提供多样化的产品，包括套件、试剂和专门的检测服务，每种产品都针对药物基因体学工作流程的不同阶段。套件和试剂广泛用于临床实验室和研究机构的常规和专门检测。对全面解读、生物资讯学支援和符合法规要求的检测的需求正在扩大服务的相关性。在治疗领域，肺癌、乳癌和大肠癌占检测量的大多数，人们对神经系统和免疫系统疾病的兴趣也日益浓厚。

在技​​术方面，聚合酵素链锁反应(PCR) 因其成本效益高、速度快，仍然是最广泛使用的。定序技术，尤其是次世代定序(NGS)，因其能够同时分析多个基因而日益普及。其他方法，例如微阵列、电泳和核酸扩增技术，也为检测生态系统做出了贡献。持续的技术创新，以及对基因-药物交互作用认识的不断提高，以及全球基因组服务覆盖范围的不断扩大，预计将在预测期内促进该市场的成长。

此外，在2025年4月举行的美国神经病学会（AAN）年会上，顶尖的神经科强调了药物基因组学在神经病学领域日益重要的作用。透过关注阿兹海默症、帕金森氏症、中风、偏头痛和多发性硬化症等疾病的遗传因素，专家们设想了模式转移，这可能会提高疗效并减少不利事件。这些趋势表明，神经系统护理领域对PGx分子诊断的临床需求日益增长，这一发展反映出一种更广泛的趋势，即在传统治疗方法之外采用基于定序的精准诊断。

整体而言，药物基因组学分子诊断产业的创新格局反映出人们正朝着更快速、更便利、更具临床可操作性的检测解决方案转变。人工智慧、照护现场系统和多体学平台等先进技术的整合，正在将PGx诊断的效用扩展到传统医院环境之外，并支持其在各个治疗领域的广泛应用。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
  • 市场驱动因素
    • 个人化医疗需求不断成长
    • 将基于NGS的诊断整合到临床工作流程中
    • 扩大监管支持和报销框架
  • 市场限制因素分析
    • 医疗专业人员和患者缺乏意识
    • 与成本相关的挑战和报销波动
  • 商业环境分析
    • 依因素（政治/法律、经济、技术）进行 SWOT 分析
    • 波特五力分析
    • COVID-19影响分析

第四章 产品业务分析

  • 药物基因体学中的分子诊断市场：产品变异分析
  • 套件和检测试剂
    • 2021-2033年市场收益估计与预测
  • 试剂
    • 2021-2033年市场收益估计与预测
  • 服务
    • 2021-2033年市场收益估计与预测

第五章治疗领域业务分析

  • 药物基因体学中的分子诊断市场：治疗领域变异分析
  • 肿瘤学
    • 2021-2033年市场收益估计与预测
    • 肺癌
    • 乳癌
    • 大肠直肠癌
    • 子宫颈癌
    • 其他的
  • 神经系统疾病
    • 2021-2033年市场收益估计与预测
  • 心血管疾病
    • 2021-2033年市场收益估计与预测
  • 免疫疾病
    • 2021-2033年市场收益估计与预测
  • 感染疾病
    • 2021-2033年市场收益估计与预测
  • 其他的
    • 2021-2033年市场收益估计与预测

第六章：技术业务分析

  • 药物基因体学中的分子诊断市场：技术波动分析
  • PCR
    • 2021-2033年市场收益估计与预测
  • 微阵列
    • 2021-2033年市场收益估计与预测
  • 定序
    • 2021-2033年市场收益估计与预测
  • 其他的
    • 2021-2033年市场收益估计与预测

第七章 区域业务分析

  • 2023 年及 2030 年各地区药物基因体学分子诊断市场份额
  • 北美洲
    • 北美药物基因体学（2021-2033）
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2021-2033年欧洲药物基因体学
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2021-2033年亚太地区药物基因体学体学分子诊断市场
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 拉丁美洲药物基因体学体学分子诊断市场（2021-2033）
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲药物基因体学体学分子诊断市场（2021-2033）
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 参与企业概况
  • 财务表现
  • 参与企业
    • 市场领导者
    • 2023年药物基因体学学分子诊断市占分析
    • 公司简介
Product Code: GVR-4-68040-697-1

Molecular Diagnostics In Pharmacogenomics Market Summary

The global molecular diagnostics in pharmacogenomics market size was estimated at USD 699.7 million in 2024 and is projected to reach USD 1, 256.38 million in 2033, growing at a CAGR of 6.84% from 2025 to 2033. This market focuses on rapid and precise genetic testing that enables tailored drug therapy, improving clinical outcomes and reducing adverse drug reactions.

Molecular diagnostics play a central role in identifying patient-specific genetic variations and are widely adopted in areas such as oncology, cardiovascular conditions, infectious diseases, and neurological disorders. Product offerings within the market span across kits, reagents, and specialized testing services, each addressing different stages of pharmacogenomic workflows. Kits and reagents are widely used in clinical laboratories and research institutions for routine and specialized assays. Services are expanding in relevance due to the need for comprehensive interpretation, bioinformatics support, and regulatory-compliant testing. The oncology segment dominates the therapeutic landscape, with lung, breast, and colorectal cancers accounting for significant test volumes, while emerging interest is observed in neurological and immunological disorders.

In terms of technology, polymerase chain reaction (PCR) remains the most widely used method due to its cost-effectiveness and speed. Sequencing technologies, particularly next-generation sequencing (NGS), are gaining ground for their ability to analyze multiple genes simultaneously. Microarrays and other methods like electrophoresis and nucleic acid amplification techniques also contribute to the testing ecosystem. Continuous innovation, along with rising awareness of gene-drug interactions and expanding access to genomic services globally, is expected to reinforce the growth of this market over the forecast period.

Moreover, at AAN's Annual Meeting in April 2025, leading neurologists underscored the emergent role of pharmacogenomics in neurology. By focusing on genetic drivers across diseases like Alzheimer's, Parkinson's, stroke, migraine, and multiple sclerosis, experts envisioned a paradigm shift toward genetically guided treatment selection, with the potential to enhance efficacy and reduce adverse events. These insights point to a growing clinical demand for PGx-enabled molecular diagnostics in neurological care a development reflecting the broader trend of sequencing-based precision diagnostics being adopted beyond traditional therapeutic boundaries.

Overall, the innovation landscape in the molecular diagnostics in pharmacogenomics industry reflects a shift toward faster, more accessible, and clinically actionable testing solutions. The integration of advanced technologies such as AI, point-of-care systems, and multi-omics platforms is expanding the utility of PGx diagnostics beyond traditional hospital settings, supporting broader adoption across diverse therapeutic areas.

Global Molecular Diagnostics In Pharmacogenomics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global molecular diagnostics in pharmacogenomics market report based on the product, therapeutic area, technology, and region:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Kits and assays
  • Reagents
  • Services
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Others
  • Neurological Disorders
  • Cardiovascular Disease
  • Immunological Disorders
  • Infectious Diseases
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • PCR
  • Microarray
  • Sequencing
  • Others
  • Regional Outlook (Revenue, USD Million, 2021- 2030)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Rising Demand for Personalized Medicine
    • 3.4.2. Integration of NGS-Based Diagnostics in Clinical Workflows
    • 3.4.3. Expanding Regulatory Support and Reimbursement Frameworks
  • 3.5. Market Restraint Analysis
    • 3.5.1. Limited Awareness Among Healthcare Providers and Patients
    • 3.5.2. Cost-Related Challenges and Reimbursement Variability
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. Covid-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Molecular Diagnostics in Pharmacogenomics Market: Product Movement Analysis
  • 4.2. Kits and Assays
    • 4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Reagents
    • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Services
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Therapeutic Area Business Analysis

  • 5.1. Molecular Diagnostics in Pharmacogenomics Market: Therapeutic Area Movement Analysis
  • 5.2. Oncology
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.2. Lung Cancer
      • 5.2.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.3. Breast Cancer
      • 5.2.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.4. Colorectal Cancer
      • 5.2.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.5. Cervical Cancer
      • 5.2.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.2.6. Others
      • 5.2.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Neurological Disorders
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Cardiovascular Disease
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Immunological Disorders
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Infectious Diseases
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Technology Business Analysis

  • 6.1. Molecular Diagnostics in Pharmacogenomics Market: Technology Movement Analysis
  • 6.2. PCR
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Microarray
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Sequencing
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Molecular Diagnostics in Pharmacogenomics Market Share, By Region, 2023 & 2030
  • 7.2. North America
    • 7.2.1. North America Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Target Disease Prevalence
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. Reimbursement Scenario
      • 7.2.2.6. U.S. Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Reimbursement Scenario
      • 7.2.3.6. Canada Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Target Disease Prevalence
      • 7.2.4.3. Competitive Scenario
      • 7.2.4.4. Regulatory Framework
      • 7.2.4.5. Reimbursement Scenario
      • 7.2.4.6. Mexico Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Reimbursement Scenario
      • 7.3.2.6. Germany Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Reimbursement Scenario
      • 7.3.3.6. UK Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Reimbursement Scenario
      • 7.3.4.6. France Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Italy Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Spain Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. Denmark Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Sweden Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Norway Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Reimbursement Scenario
      • 7.4.2.6. Japan Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Reimbursement Scenario
      • 7.4.3.6. China Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Reimbursement Scenario
      • 7.4.4.6. India Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. South Korea Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. Australia Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. Thailand Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Reimbursement Scenario
      • 7.5.2.6. Brazil Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Reimbursement Scenario
      • 7.5.3.6. Argentina Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Reimbursement Scenario
      • 7.6.2.6. South Africa Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Reimbursement Scenario
      • 7.6.3.6. Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. Reimbursement Scenario
      • 7.6.4.6. UAE Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. Kuwait Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant's Overview
  • 8.2. Financial Performance
  • 8.3. Participant Categorization
    • 8.3.1. Market Leaders
    • 8.3.2. Molecular Diagnostics in Pharmacogenomics Market Share Analysis, 2023
    • 8.3.3. Company Profiles
      • 8.3.3.1. Roche Diagnostics
        • 8.3.3.1.1. Company Overview
        • 8.3.3.1.2. Financial Performance
        • 8.3.3.1.3. Product Benchmarking
        • 8.3.3.1.4. Strategic Initiatives
      • 8.3.3.2. QIAGEN
        • 8.3.3.2.1. Company Overview
        • 8.3.3.2.2. Financial Performance
        • 8.3.3.2.3. Product Benchmarking
        • 8.3.3.2.4. Strategic Initiatives
      • 8.3.3.3. Thermo Fisher Scientific
        • 8.3.3.3.1. Company Overview
        • 8.3.3.3.2. Financial Performance
        • 8.3.3.3.3. Product Benchmarking
        • 8.3.3.3.4. Strategic Initiatives
      • 8.3.3.4. Illumina, Inc.
        • 8.3.3.4.1. Company Overview
        • 8.3.3.4.2. Financial Performance
        • 8.3.3.4.3. Product Benchmarking
        • 8.3.3.4.4. Strategic Initiatives
      • 8.3.3.5. Agilent Technologies
        • 8.3.3.5.1. Company Overview
        • 8.3.3.5.2. Financial Performance
        • 8.3.3.5.3. Product Benchmarking
        • 8.3.3.5.4. Strategic Initiatives
      • 8.3.3.6. Abbott Molecular
        • 8.3.3.6.1. Company Overview
        • 8.3.3.6.2. Financial Performance
        • 8.3.3.6.3. Product Benchmarking
        • 8.3.3.6.4. Strategic Initiatives
      • 8.3.3.7. Genomind
        • 8.3.3.7.1. Company Overview
        • 8.3.3.7.2. Financial Performance
        • 8.3.3.7.3. Product Benchmarking
        • 8.3.3.7.4. Strategic Initiatives
      • 8.3.3.8. OneOme
        • 8.3.3.8.1. Company Overview
        • 8.3.3.8.2. Financial Performance
        • 8.3.3.8.3. Product Benchmarking
        • 8.3.3.8.4. Strategic Initiatives
      • 8.3.3.9. Myriad Genetics
        • 8.3.3.9.1. Company Overview
        • 8.3.3.9.2. Financial Performance
        • 8.3.3.9.3. Product Benchmarking
        • 8.3.3.9.4. Strategic Initiatives
      • 8.3.3.10. Invitae (formerly YouScript)
        • 8.3.3.10.1. Company Overview
        • 8.3.3.10.2. Financial Performance
        • 8.3.3.10.3. Product Benchmarking
        • 8.3.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 Molecular Diagnostics in Pharmacogenomics Market - Industry Snapshot & Key Buying Criteria, 2021 - 2033
  • Table 2 Global Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 3 Global Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 4 Global Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 5 Global Molecular Diagnostics in Pharmacogenomics Market, by region, 2021 - 2033 (USD Million)
  • Table 6 Molecular Diagnostics in Pharmacogenomics- Key market driver analysis
  • Table 7 Molecular Diagnostics in Pharmacogenomics- Key market restraint analysis
  • Table 8 North America Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 10 North America Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 11 North America Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 12 U.S. Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 13 U.S. Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 14 U.S. Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 15 Canada Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 16 Canada Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 17 Canada Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 18 Mexico Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 19 Mexico Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 20 Mexico Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 21 Europe Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
  • Table 22 Europe Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 23 Europe Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 24 Europe Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 25 Germany Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 26 Germany Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 27 Germany Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 28 UK Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 29 UK Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 30 UK Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 31 France Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 32 France Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 33 France Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 34 Italy Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 35 Italy Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 36 Italy Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 37 Spain Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 38 Spain Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 39 Spain Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 40 Denmark Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 41 Denmark Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 42 Denmark Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 43 Sweden Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 44 Sweden Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 45 Sweden Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 46 Norway Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 47 Norway Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 48 Norway Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 49 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 52 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 53 Japan Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 54 Japan Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 55 Japan Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 56 China Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 57 China Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 58 China Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 59 India Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 60 India Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 61 India Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 62 Australia Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 63 Australia Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 64 Australia Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 65 South Korea Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 66 South Korea Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 67 South Korea Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 68 Thailand Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 69 Thailand Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 70 Thailand Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 71 Latin America Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
  • Table 72 Latin America Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 73 Latin America Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 74 Latin America Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 75 Brazil Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 76 Brazil Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 77 Brazil Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 78 Argentina Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 79 Argentina Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 80 Argentina Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 81 MEA Molecular Diagnostics in Pharmacogenomics Market, by country, 2021 - 2033 (USD Million)
  • Table 82 MEA Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 83 MEA Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 84 MEA Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 85 South Africa Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 86 South Africa Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 87 South Africa Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 88 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 90 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 91 UAE Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 92 UAE Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 93 UAE Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area
  • Table 94 Kuwait Molecular Diagnostics in Pharmacogenomics Market, by product, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Molecular Diagnostics in Pharmacogenomics Market, by technology, 2021 - 2033 (USD Million)
  • Table 96 Kuwait Molecular Diagnostics in Pharmacogenomics Market, By Therapeutic Area

List of Figures

  • Fig. 1 Molecular Diagnostics in Pharmacogenomics Market Segmentation
  • Fig. 2 Global Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 3 Molecular Diagnostics in Pharmacogenomics Market Dynamics
  • Fig. 4 Key Opportunities Prioritized, 2021
  • Fig. 5 Molecular Diagnostics in Pharmacogenomics Market - Porter's Analysis
  • Fig. 6 Molecular Diagnostics in Pharmacogenomics Market - PESTEL Analysis
  • Fig. 7 Molecular Diagnostics in Pharmacogenomics Revenue Share, By Product, 2023 & 2030
  • Fig. 8 Kits and assays Market, 2021 - 2033 (USD Million)
  • Fig. 9 Reagents Market, 2021 - 2033 (USD Million)
  • Fig. 10 Services Market, 2021 - 2033 (USD Million)
  • Fig. 11 Molecular Diagnostics in Pharmacogenomics Revenue Share, By Technology, 2023 & 2030
  • Fig. 12 PCR Market, 2021 - 2033 (USD Million)
  • Fig. 13 Microarray Market, 2021 - 2033 (USD Million)
  • Fig. 14 Sequencing Market, 2021 - 2033 (USD Million)
  • Fig. 15 Others Market, 2021 - 2033 (USD Million)
  • Fig. 16 Molecular Diagnostics in Pharmacogenomics Revenue Share, By Therapeutic Area, 2023 & 2030
  • Fig. 17 Oncology Market, 2021 - 2033 (USD Million)
  • Fig. 18 Lung Cancer Market, 2021 - 2033 (USD Million)
  • Fig. 19 Breast Cancer Market, 2021 - 2033 (USD Million)
  • Fig. 20 Colorectal Cancer Market, 2021 - 2033 (USD Million)
  • Fig. 21 Cervical Cancer Market, 2021 - 2033 (USD Million)
  • Fig. 22 Others Market, 2021 - 2033 (USD Million)
  • Fig. 23 Neurological Disorders Market, 2021 - 2033 (USD Million)
  • Fig. 24 Cardiovascular Disease Market, 2021 - 2033 (USD Million)
  • Fig. 25 Immunological Disorders Market, 2021 - 2033 (USD Million)
  • Fig. 26 Infectious Diseases Market, 2021 - 2033 (USD Million)
  • Fig. 27 Others Market, 2021 - 2033 (USD Million)
  • Fig. 28 Molecular Diagnostics in Pharmacogenomics Revenue Share, By Region, 2023 & 2030
  • Fig. 29 North America Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 30 US Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 31 Canada Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 32 Mexico Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 33 Europe Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 34 Germany Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 35 UK Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 36 France Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 37 Italy Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 38 Spain Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 39 Denmark Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 40 Sweden Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 41 Norway Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 42 Asia Pacific Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 43 Japan Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 44 China Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 45 India Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 46 Australia Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 47 South Korea Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 48 Thailand Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 49 Latin America Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 50 Brazil Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 51 Argentina Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 52 MEA Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 53 South Africa Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 54 Saudi Arabia Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 55 UAE Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)
  • Fig. 56 Kuwait Molecular Diagnostics in Pharmacogenomics Market, 2021 - 2033 (USD Million)